# Calidi Biotherapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Calidi Biotherapeutics, Inc.).

## Overview

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered virotherapies and related cell-based delivery platforms for cancer treatment. The company is advancing product candidates such as CLD-101 and CLD-201, while also building the manufacturing, regulatory, and intellectual property infrastructure needed to support future clinical and commercial development. It currently has no product sales and remains dependent on external financing to fund research, development, and operations. Calidi is headquartered in the United States and also operates through subsidiaries in Germany and Australia to support parts of its development and trial activities.

## Products & services

• CLD-101 oncolytic virotherapy program
• CLD-201 virotherapy/cell therapy program
• Preclinical and clinical development services
• Drug product and drug supply manufacturing for trials
• Intellectual property licensing and development

- **Oncolytic virotherapy programs** (70%) — Engineered virus-based cancer therapeutics designed to attack tumors and stimulate anti-tumor immune responses.
- **Cell-based delivery platforms** (20%) — Cell therapy approaches used to deliver therapeutic payloads and improve targeting of tumor sites.
- **Preclinical and clinical development** (10%) — Research, toxicology, trial execution, and regulatory work required to advance product candidates.

- CLD-101 oncolytic virotherapy program
- CLD-201 virotherapy/cell therapy program
- Preclinical and clinical development services
- Drug product and drug supply manufacturing for trials
- Intellectual property licensing and development

## Customers

Calidi does not currently sell commercial products, so its near-term 'customers' are primarily research partners, clinical investigators, contract manufacturers, and potential future licensing or commercialization partners. In a commercial setting, the company’s therapies would ultimately be used by oncology physicians and hospitals treating patients with solid tumors or other cancers targeted by its programs. The company also relies on universities and licensors for access to underlying technology, including agreements with Northwestern University, City of Hope, and the University of Chicago. If its programs progress successfully, pharmaceutical partners would be important buyers of development rights, manufacturing support, or regional commercialization rights.

- **Clinical trial ecosystem** (primary) — Hospitals, investigators, and trial vendors that support the testing of CLD-101 and CLD-201 in patients.
- **Manufacturing and supply partners** (primary) — Specialty manufacturers and suppliers that produce clinical-grade viral and cell therapy materials for development programs.
- **Technology licensors** (secondary) — Universities and research institutions that license foundational IP and may receive contingent payments if programs advance.
- **Future commercialization partners** (emerging) — Biopharma companies that could license, co-develop, or commercialize Calidi’s candidates after clinical validation.

- Clinical investigators and trial sites running Calidi-sponsored studies
- Contract manufacturers producing drug product and clinical supply
- University licensors and research institutions providing IP access
- Potential pharma partners seeking licensing or co-development rights
- Future oncology treatment centers and physicians if products are approved

## Geography

Calidi is based in the United States, where its principal executive and administrative offices and laboratory facility are located in San Diego. The company also operates through wholly owned subsidiaries in Germany and Australia, reflecting a development footprint that extends beyond the U.S. for research, staffing, and clinical trial execution. Management specifically noted foreign vendors and employees in Europe, particularly Germany, and a subsidiary in Australia formed to support a portion of planned clinical trial activities for the SNV1 program. Because the company is still pre-commercial, geography matters mainly through where R&D work is performed, where trial activity is conducted, and where foreign-currency costs are incurred.

- United States is the core operating base and headquarters market
- San Diego facility serves as principal office and laboratory site
- Germany exposure comes through wholly owned subsidiary StemVac GmbH
- Australia subsidiary supports planned SNV1 clinical trial activity
- Foreign vendors in Europe create some non-U.S. operating exposure

## Strategy

Calidi’s strategy is centered on advancing its current and future product candidates through preclinical and clinical development while preserving enough capital to remain a going concern. The company is also building the manufacturing, regulatory, and intellectual property capabilities needed to support eventual approval and commercialization. Because it has no product revenue, partnering is strategically important: management expects collaboration agreements, strategic alliances, or licensing arrangements to help fund development and reduce the burden of building a full commercial infrastructure alone. In the near term, the company’s success depends on clinical progress, capital raises, and maintaining access to specialized manufacturing and trial execution capabilities.

- **Raise additional capital** (short-term) — The company has stated it does not have sufficient cash to support operations for at least one year and needs funding to continue development.
- **Advance clinical and preclinical programs** (medium-term) — Clinical progress is required to create value, support regulatory filings, and eventually enable commercialization.
- **Build partnering optionality** (medium-term) — Third-party partnerships could provide non-dilutive funding and commercialization capabilities that Calidi does not yet have.

- Advance CLD-101 and CLD-201 through preclinical and clinical milestones
- Secure additional capital through equity, debt, or partnering
- Use collaboration or licensing deals to offset development and commercialization costs
- Expand intellectual property around its virotherapy platform
- Maintain manufacturing access for clinical drug product and supply
- Support international trial activity through foreign subsidiaries

## Risks

Calidi faces substantial going-concern and financing risk because it has no product revenue and expects continuing operating losses as it funds research, trials, and regulatory work. Clinical-stage biotechnology companies also face high technical and regulatory risk: product candidates may fail in preclinical testing, clinical trials, or regulatory review, which would reduce or eliminate future value. The company is exposed to manufacturing and supply-chain risk because it depends on third-party vendors for clinical drug product and supply, and those arrangements can be costly or disrupted. It also has foreign operating exposure through Germany and Australia, which introduces currency, staffing, and cross-border execution risk, while broader market conditions can affect its ability to raise capital on acceptable terms.

- **Insufficient liquidity and going-concern uncertainty** [critical] — Management disclosed that current cash is not sufficient to support operations for at least one year and that substantial additional funding is required.
- **Clinical trial and development failure** [high] — The company’s value depends on advancing unapproved product candidates through preclinical and clinical stages, where failure rates are high.
- **Dependence on external financing and capital markets** [high] — Without product revenue, the company must fund operations through equity offerings, debt, or partnerships, which may not be available on favorable terms.
- **Manufacturing and vendor concentration** [medium] — Clinical drug product and supply are sourced from vendors, making timelines and costs vulnerable to third-party performance.
- **Foreign operating and currency exposure** [medium] — Operations in Germany and Australia and use of European vendors create exposure to exchange-rate and cross-border execution issues.

- Going-concern risk due to insufficient cash and ongoing losses
- Clinical development failure risk for CLD-101 and CLD-201
- Regulatory approval risk if candidates do not meet safety or efficacy standards
- Financing risk from dependence on equity, debt, or partnering markets
- Manufacturing and supply risk from reliance on third-party clinical vendors
- Foreign exchange and cross-border execution risk in Germany and Australia
- IP and license obligation risk from university agreements and contingent payments

## Accounting

Calidi’s financial statements are dominated by judgment-heavy estimates typical of a development-stage biotech company. Because it has no product revenue, the key accounting issues are expense recognition for R&D, valuation of equity financings and warrants, and the treatment of lease and vendor commitments that support clinical operations. The company also has contingent obligations under university license agreements, which require assessment of whether future payments are probable and measurable. Lease accounting is relevant because the San Diego office and laboratory facility, as well as other equipment and office leases, create future minimum payments that affect reported liabilities and cash commitments. Investors should also watch for going-concern disclosures, since management has explicitly concluded that there is substantial doubt about the company’s ability to continue as a going concern.

- **Going concern assessment** — Affects liquidity analysis, valuation, and financing assumptions
- **Research and development expense recognition** — Affects operating loss and quarterly volatility
- **Lease accounting** — Affects balance sheet liabilities and cash commitment disclosure
- **Contingent license obligations** — Affects contingent liability disclosure and future cash outflows

- No product revenue yet, so results are driven by R&D and G&A expense recognition
- Going-concern assessment is a major disclosure and valuation issue
- Lease accounting affects reported liabilities for offices, labs, and equipment
- Contingent license payments may create future obligations if programs advance
- Equity financings and warrants can create complex dilution and fair value issues
- Clinical vendor commitments affect future cash needs and accruals

---

*Last updated: 2026-04-28T14:25:15.199463+00:00*